News

Article

European Medicines Agency Changes Procedures for Orphan Drug Fees

EMA streamlines orphan drug application procedure.

The European Medicines Agency (EMA) has stopped requiring sponsors of orphan drugs to inform EMA of their intention to submit an application to be eligible for a fee reduction. This change is part of EMA’s effort to streamline the procedures for fee reductions and is effective immediately.

Drugs that have been granted orphan designation by the European Commission on the recommendation of the EMA’s Committee for Orphan Medicinal Products are eligible for fee reductions for a range of regulatory activities including pre-authorization activities such as protocol assistance, the application for marketing authorization, and inspections. EMA will no longer require additional information from the sponsor before submitting an application eligible for fee reduction for orphan drugs.
EMA has removed “Procedural Advice on Fee Reductions for Designated Orphan Medicinal Products” from the Agency’s website and the standard operating procedure on processing of fee reductions for designated orphan drug products (SOP/H/3048) is now obsolete.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More